ArticleRadiology2025
Feasibility of Auditing Preoperative Breast MRI for Extent-of-Disease Evaluation Using the BI-RADS v2025 Manual.
Article in Radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- How BI-RADS v2025 Helps Patients: New Audits and Method of Detection.Korean journal of radiology · 2026Review
- Survey of the Senologic International Society (SIS) on the Use of Preoperative Breast MRI in Early-Stage Breast Cancer: A Global Perspective on Current Practice.European journal of breast health · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
Abstract
Background The forthcoming Breast Imaging Reporting and Data System (BI-RADS) version 2025 (hereafter, v2025) manual recommends auditing breast MRI examinations performed to evaluate the extent of disease in women newly diagnosed with breast cancer. Purpose To investigate the feasibility of this recommended audit using preoperative breast MRI examinations performed over 2 years, report the calculated metrics, and identify any clinical or imaging characteristics associated with improved MRI performance metrics. Materials and Methods Consecutive breast MRI examinations performed from January 2021 to December 2022 at The University of Texas MD Anderson Cancer Center were retrospectively reviewed, excluding screening, diagnostic, neoadjuvant chemotherapy response, and nondiagnostic or incomplete preoperative MRI examinations. Recommended audit calculations were performed as described in the BI-RADS v2025 manual: abnormal interpretation rate (AIR) (percentage of positive preoperative MRI examinations), positive predictive value of biopsies recommended (PPV2) (percentage of all distinct BI-RADS category 4 or 5 findings, not examinations, with a tissue diagnosis of cancer at image-guided biopsy), positive predictive value of biopsies performed (PPV3) (percentage of BI-RADS category 4 or 5 findings, not examinations, with preoperative image-guided biopsy revealing a tissue diagnosis of cancer), and additional cancer detection rate (ACDR) (number of additional malignant lesions diagnosed beyond the primary cancer per 1000 MRI examinations). Total time collecting data and performing calculations was recorded. Characteristics of benign and malignant BI-RADS 4 or 5 lesions were compared using the Wilcoxon rank sum test and Fisher exact test. Logistic regression was used to determine characteristics associated with malignancy. Results A total of 1533 preoperative MRI examinations were included (median patient age, 54.6 years; IQR, 45.5-65.2 years; all female), with 464 MRI examinations revealing 609 suspicious breast findings. Subsequent image-guided biopsy for 432 of these findings revealed 139 malignancies. The overall AIR was 30.3% (95% CI: 28.0, 32.6), overall PPV2 was 22.8% (95% CI: 19.5, 26.1), overall PPV3 was 32.2% (95% CI: 27.8, 36.6), and overall ACDR was 90.7 per 1000 examinations (95% CI: 74.3, 107.1). Seven radiologists spent a combined total of 141 hours collecting data and performing audit calculations. Older patient age (odds ratio, 1.04; 95% CI: 1.02, 1.05;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.